- Home
- CFBK vs VTYX Comparison
CFBK vs VTYX Comparison
Compare CFBK & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFBK
- VTYX
- Stock Information
- Founded
- CFBK 1892
- VTYX 2018
- Country
- CFBK United States
- VTYX United States
- Employees
- CFBK N/A
- VTYX N/A
- Industry
- CFBK Major Banks
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- CFBK Finance
- VTYX Health Care
- Exchange
- CFBK Nasdaq
- VTYX Nasdaq
- Market Cap
- CFBK 154.9M
- VTYX 154.9M
- IPO Year
- CFBK 1998
- VTYX 2021
- Fundamental
- Price
- CFBK $24.17
- VTYX $2.07
- Analyst Decision
- CFBK Buy
- VTYX Buy
- Analyst Count
- CFBK 1
- VTYX 4
- Target Price
- CFBK $29.00
- VTYX $11.33
- AVG Volume (30 Days)
- CFBK 36.5K
- VTYX 2.2M
- Earning Date
- CFBK 08-05-2025
- VTYX 08-07-2025
- Dividend Yield
- CFBK 1.15%
- VTYX N/A
- EPS Growth
- CFBK N/A
- VTYX N/A
- EPS
- CFBK 2.28
- VTYX N/A
- Revenue
- CFBK $47,663,000.00
- VTYX N/A
- Revenue This Year
- CFBK $35.39
- VTYX N/A
- Revenue Next Year
- CFBK $10.11
- VTYX N/A
- P/E Ratio
- CFBK $10.50
- VTYX N/A
- Revenue Growth
- CFBK 1.22
- VTYX N/A
- 52 Week Low
- CFBK $18.20
- VTYX $0.78
- 52 Week High
- CFBK $31.17
- VTYX $3.39
- Technical
- Relative Strength Index (RSI)
- CFBK 60.31
- VTYX 47.05
- Support Level
- CFBK $23.30
- VTYX $2.05
- Resistance Level
- CFBK $24.07
- VTYX $2.51
- Average True Range (ATR)
- CFBK 0.36
- VTYX 0.20
- MACD
- CFBK 0.01
- VTYX -0.07
- Stochastic Oscillator
- CFBK 85.19
- VTYX 2.44
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.